keyword
MENU ▼
Read by QxMD icon Read
search

Leucemie

keyword
https://www.readbyqxmd.com/read/27595286/prevalence-and-risk-factors-of-iron-overload-after-hematopoietic-stem-cell-transplantation-for-childhood-acute-leukemia-a-lea-study
#1
A Sirvent, P Auquier, C Oudin, Y Bertrand, S Bohrer, P Chastagner, M Poirée, J Kanold, S Thouvenin, Y Perel, D Plantaz, M-D Tabone, K Yakouben, V Gandemer, P Lutz, N Sirvent, C Vercasson, J Berbis, H Chambost, G Leverger, A Baruchel, G Michel
Data on post-transplant iron overload (IO) are scarce in pediatrics. We conducted a prospective multicenter cohort study (Leucémie de l'Enfant et de l'Adolescent cohort) to determine the prevalence and risk factors of IO in 384 acute leukemia survivors transplanted during childhood. Prevalence of IO (ferritin level ⩾350 ng/mL) was 42.2% (95%CI 37.2-47.2%). Factors significantly associated with IO were: 1) in univariate analysis: older age at transplant (P<0.001), allogeneic versus autologous transplantation (P<0...
September 5, 2016: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/27324280/zoledronate-in-combination-with-chemotherapy-and-surgery-to-treat-osteosarcoma-os2006-a-randomised-multicentre-open-label-phase-3-trial
#2
Sophie Piperno-Neumann, Marie-Cécile Le Deley, Françoise Rédini, Hélène Pacquement, Perrine Marec-Bérard, Philippe Petit, Hervé Brisse, Cyril Lervat, Jean-Claude Gentet, Natacha Entz-Werlé, Antoine Italiano, Nadège Corradini, Emmanuelle Bompas, Nicolas Penel, Marie-Dominique Tabone, Anne Gomez-Brouchet, Jean-Marc Guinebretière, Eric Mascard, François Gouin, Aurélie Chevance, Naïma Bonnet, Jean-Yves Blay, Laurence Brugières
BACKGROUND: Based on preclinical data for the antitumour effect of zoledronate in osteosarcoma, we assessed whether zoledronate combined with chemotherapy and surgery improved event-free survival in children and adults with osteosarcoma. METHODS: In this randomised, multicentre, open-label, phase 3 trial (OS2006), patients aged between 5 years and 50 years with newly diagnosed high-grade osteosarcoma were randomly assigned to receive standard chemotherapy with or without ten zoledronate intravenous infusions (four preoperative and six postoperative)...
August 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27185246/employment-in-french-young-adult-survivors-of-childhood-leukemia-an-lea-study-for-leucemies-de-l-enfant-et-de-l-adolescent-childhood-and-adolescent-leukemia
#3
Julie Berbis, Céline Reggio, Gérard Michel, Pascal Chastagner, Yves Bertrand, Justyna Kanold, Nicolas Sirvent, Dominique Plantaz, André Baruchel, Marie-Dominique Tabone, Floriane Garnier, Marie-Pascale Lehucher-Michel, Pascal Auquier
PURPOSE: Our principal aim was to assess the occupational outcomes of French survivors of childhood leukemia, compared to national population. The secondary objective was to identify determinants linked with employment stability after childhood leukemia. METHODS: All survivors aged 15 and over enrolled in the French LEA Cohort (Childhood and Adolescent Leukemia) were included. Occupational data were self-reported. The occupational distributions expected in the cohort for each age range were established based on the distribution in France as reference, and comparisons between observed and expected distributions were performed...
May 17, 2016: Journal of Cancer Survivorship: Research and Practice
https://www.readbyqxmd.com/read/26790711/-management-of-the-cardiovascular-disease-risk-during-nilotinib-treatment-in-chronic-myeloid-leukemia-2015-recommendations-from-the-france-intergroupe-des-leuc%C3%A3-mies-my%C3%A3-lo%C3%A3-des-chroniques
#4
Delphine Rea, Shanti Ame, Aude Charbonnier, Valérie Coiteux, Pascale Cony-Makhoul, Martine Escoffre-Barbe, Gabriel Etienne, Martine Gardembas, Agnès Guerci-Bresler, Laurence Legros, Franck Nicolini, Michel Tulliez, Eric Hermet, Françoise Huguet, Hyacinthe Johnson-Ansah, Simona Lapusan, Philippe Quittet, Philippe Rousselot, François-Xavier Mahon, Emmanuel Messas
Tyrosine kinase inhibitors targeting the BCR-ABL oncoprotein represent an outstanding progress in chronic myeloid leukemia and long-term progression-free survival has become a reality for a majority of patients. However, tyrosine kinase inhibitors may at best chronicize rather than cure the disease thus current recommendation is to pursue treatment indefinitely. As a consequence, high quality treatment and care must integrate optimal disease control and treatment tolerability. Tyrosine kinase inhibitors have an overall favorable safety profile in clinical practice since most adverse events are mild to moderate in intensity...
February 2016: Bulletin du Cancer
https://www.readbyqxmd.com/read/26460308/genome-wide-association-study-of-event-free-survival-in-diffuse-large-b-cell-lymphoma-treated-with-immunochemotherapy
#5
Hervé Ghesquieres, Susan L Slager, Fabrice Jardin, Amelie S Veron, Yan W Asmann, Matthew J Maurer, Thierry Fest, Thomas M Habermann, Marie C Bene, Anne J Novak, Sylvain Mareschal, Corinne Haioun, Thierry Lamy, Stephen M Ansell, Herve Tilly, Thomas E Witzig, George J Weiner, Andrew L Feldman, Ahmet Dogan, Julie M Cunningham, Curtis L Olswold, Thierry Jo Molina, Brian K Link, Noel Milpied, David G Cox, Gilles A Salles, James R Cerhan
PURPOSE: We performed a multistage genome-wide association study to identify inherited genetic variants that predict outcome in diffuse large B-cell lymphoma patients treated with immunochemotherapy. METHODS: We conducted a meta-analysis of two genome-wide association study data sets, one from the LNH2003B trial (N = 540), a prospective clinical trial from the Lymphoma Study Association, and the other from the Molecular Epidemiology Resource study (N = 312), a prospective observational study from the University of Iowa-Mayo Clinic Lymphoma Specialized Program of Research Excellence...
November 20, 2015: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/26438544/embryonal-tumors-with-multilayered-rosettes-in-children-the-sfce-experience
#6
Meryl Horwitz, Christelle Dufour, Pierre Leblond, Franck Bourdeaut, Cécile Faure-Conter, Anne-Isabelle Bertozzi, Marie Bernadette Delisle, Gilles Palenzuela, Anne Jouvet, Didier Scavarda, Matthieu Vinchon, Laetitia Padovani, Jean Gaudart, Dominique Figarella Branger, Nicolas Andre
PURPOSES: The purpose of this study was to retrospectively study embryonal tumors with multilayered rosettes (ETMR), a rare new entity that gathers ETAN-TR (embryonal tumor with abundant neuropil and true rosettes), ependymoblastomas, and medulloepitheliomas, in order to improve their descriptions and try to better define therapeutic modalities. METHODS: Patients with ETMR, ETAN-TR, ependymoblastoma, and medulloepithelioma treated in SFCE centres (Société Française de lutte contre les Cancers et les leucémies de l'Enfant et de l'adolescent) since 2000 were collected...
February 2016: Child's Nervous System: ChNS: Official Journal of the International Society for Pediatric Neurosurgery
https://www.readbyqxmd.com/read/26404501/prognostic-value-of-self-reported-fatigue-on-overall-survival-in-patients-with-myelodysplastic-syndromes-a-multicentre-prospective-observational-cohort-study
#7
MULTICENTER STUDY
Fabio Efficace, Gianluca Gaidano, Massimo Breccia, Maria Teresa Voso, Francesco Cottone, Emanuele Angelucci, Giovanni Caocci, Reinhard Stauder, Dominik Selleslag, Mirjam Sprangers, Uwe Platzbecker, Alessandra Ricco, Grazia Sanpaolo, Odile Beyne-Rauzy, Francesco Buccisano, Giuseppe A Palumbo, David Bowen, Khanh Nguyen, Pasquale Niscola, Marco Vignetti, Franco Mandelli
BACKGROUND: The clinical presentation of myelodysplastic syndromes is highly variable and so accurate prediction of outcomes in these patients is crucial. We aimed to assess whether self-reported fatigue severity predicts overall survival beyond gold-standard prognostic indices in patients with higher-risk myelodysplastic syndromes. METHODS: We did a multicentre, prospective, observational, cohort study of patients from 37 centres in Europe, USA, and east Asia. Adults (≥18 years) with myelodysplastic syndromes were consecutively enrolled within 6 months of diagnosis with an intermediate-2-risk or high-risk score according to the International Prognostic Scoring System (IPSS)...
November 2015: Lancet Oncology
https://www.readbyqxmd.com/read/26384474/cd180-expression-in-b-cell-lymphomas-a-multicenter-geil-study
#8
Caroline Mayeur-Rousse, Julien Guy, Laurent Miguet, Sabrina Bouyer, Franck Geneviève, Nelly Robillard, Françoise Solly, Aida Maar, Marie C Bené, Laurent Mauvieux
CD180, a related member of the Toll-like receptor family, is lost or underexpressed at the plasma membrane in circulating cells of various B-cell lymphomas except marginal zone lymphomas (MZL). In order to confirm its clinical relevance in routine analysis, we evaluated prospectively the expression of CD180 in 236 patients from 5 French University Hospital laboratories on behalf of the GEIL. Highly comparable results were obtained in all centers using the EuroFlow standardization protocol. We observed that CD180 median fluorescence (MdFI) was significantly higher in MZL and hairy cell leukaemia (HCL) compared to all other B-cell proliferations (P < 0...
September 2016: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/25962541/-post-hematopietic-stem-cell-transplant-complications
#9
REVIEW
Eva de Berranger, Charlotte Jubert, Gérard Michel
Under the long-term monitoring of patients treated in childhood or adolescence for cancer, we present in this article the long-term monitoring and therefore possible effects of patients who underwent allergenic hematopoietic stem cell transplantation. This article is based on a collaborative effort organized by the French Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC), which took place during the 4th day of allograft harmonization practices. Patients affected are children and young adults (0-25 years)...
July 2015: Bulletin du Cancer
https://www.readbyqxmd.com/read/25284463/incidence-and-risk-factors-for-cataract-after-haematopoietic-stem-cell-transplantation-for-childhood-leukaemia-an-lea-study
#10
Meryl Horwitz, Pascal Auquier, Vincent Barlogis, Audrey Contet, Maryline Poiree, Justyna Kanold, Yves Bertrand, Dominique Plantaz, Claire Galambrun, Julie Berbis, Virginie Villes, Pascal Chastagner, Nicolas Sirvent, Claire Oudin, Gérard Michel
Cataract was prospectively assessed by serial slip lamp tests in 271 patients included in the Leucémie Enfants Adolescents (LEA) programme, the French cohort of childhood leukaemia survivors. All had received haematopoietic stem cell transplantation (HSCT) after total body irradiation (TBI, n = 201) or busulfan-based (n = 70) myeloablative conditioning regimen. TBI was fractionated in all but six patients. The mean duration of follow-up from HSCT was 10·3 years. Cataract was observed in 113/271 patients (41·7%); 9/113 (8·1%) needed surgery...
February 2015: British Journal of Haematology
https://www.readbyqxmd.com/read/24732592/high-level-of-soluble-programmed-cell-death-ligand-1-in-blood-impacts-overall-survival-in-aggressive-diffuse-large-b-cell-lymphoma-results-from-a-french-multicenter-clinical-trial
#11
D Rossille, M Gressier, D Damotte, D Maucort-Boulch, C Pangault, G Semana, S Le Gouill, C Haioun, K Tarte, T Lamy, N Milpied, T Fest
The dosage of soluble programmed cell death ligand 1 (sPD-L1) protein in the blood of adults with cancer has never been performed in a prospective patient cohort. We evaluated the clinical impact of sPD-L1 level measured at the time of diagnosis for newly diagnosed diffuse large B-cell lymphoma (DLBCL). Soluble PD-L1 was measured in the plasma of 288 patients enrolled in a multicenter, randomized phase III trial that compared R-high-dose chemotherapy with R-CHOP. The median follow-up was 41.4 months. A cutoff of 1...
December 2014: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/24639445/cohort-profile-the-french-childhood-cancer-survivor-study-for-leukaemia-lea-cohort
#12
MULTICENTER STUDY
Julie Berbis, Gérard Michel, André Baruchel, Yves Bertrand, Pascal Chastagner, François Demeocq, Justyna Kanold, Guy Leverger, Dominique Plantaz, Marilyne Poirée, Jean-Louis Stephan, Pascal Auquier, Audrey Contet, Jean-Hugues Dalle, Stéphane Ducassou, Virginie Gandemer, Patrick Lutz, Nicolas Sirvent, Marie-Dominique Tabone, Sandrine Thouvenin-Doulet
The main aim of the Leucémies de l'Enfant et l'Adolescent (LEA) project (Childhood and Adolescent Leukaemia) is to study the determinants (medical, socioeconomic, behavioural and environmental) of medium- and long-term outcomes of patients treated for childhood acute leukaemia (AL). The LEA study began in 2004 and is based on a French multicentric prospective cohort. Included are children treated for AL since January 1980 (incident and prevalent cases), surviving at month 24 for myeloblastic AL and lymphoblastic AL grafted in first complete remission or at month 48 for lymphoblastic AL not grafted in first complete remission...
February 2015: International Journal of Epidemiology
https://www.readbyqxmd.com/read/24375487/azacitidine-in-untreated-acute-myeloid-leukemia-a-report-on-149-patients
#13
MULTICENTER STUDY
Sylvain Thépot, Raphael Itzykson, Valerie Seegers, Christian Recher, Emmanuel Raffoux, Bruno Quesnel, Jacques Delaunay, Thomas Cluzeau, Anne Marfaing Koka, Aspasia Stamatoullas, Marie-Pierre Chaury, Caroline Dartigeas, Stéphane Cheze, Anne Banos, Pierre Morel, Isabelle Plantier, Anne-Laure Taksin, Jean Pierre Marolleau, Cecile Pautas, Xavier Thomas, Francoise Isnard, Blandine Beve, Yasmine Chait, Agnes Guerci, Norbert Vey, Francois Dreyfus, Lionel Ades, Norbert Ifrah, Herve Dombret, Pierre Fenaux, Claude Gardin
Limited data are available on azacitidine (AZA) treatment and its prognostic factors in acute myeloid leukemia (AML). One hundred and forty-nine previously untreated AML patients considered ineligible for intensive chemotherapy received AZA in a compassionate patient-named program. AML diagnosis was de novo, post-myelodysplastic syndromes (MDS), post-MPN, and therapy-related AML in 51, 55, 13, and 30 patients, respectively. Median age was 74 years, median white blood cell count (WBC) was 3.2 × 10⁹ /L and 58% of the patients had ≥ 30% marrow blasts...
April 2014: American Journal of Hematology
https://www.readbyqxmd.com/read/23975179/prognostic-impact-of-day-15-blast-clearance-in-risk-adapted-remission-induction-chemotherapy-for-younger-patients-with-acute-myeloid-leukemia-long-term-results-of-the-multicenter-prospective-lam-2001-trial-by-the-goelams-study-group
#14
RANDOMIZED CONTROLLED TRIAL
Sarah Bertoli, Pierre Bories, Marie C Béné, Sylvie Daliphard, Bruno Lioure, Arnaud Pigneux, Norbert Vey, Jacques Delaunay, Vincent Leymarie, Isabelle Luquet, Odile Blanchet, Pascale Cornillet-Lefebvre, Mathilde Hunault, Didier Bouscary, Nathalie Fegueux, Philippe Guardiola, François Dreyfus, Jean Luc Harousseau, Jean Yves Cahn, Norbert Ifrah, Christian Récher
Early response to chemotherapy has a major prognostic impact in acute myeloid leukemia patients treated with a double induction strategy. Less is known about patients treated with standard-dose cytarabine and anthracycline. We designed a risk-adapted remission induction regimen in which a second course of intermediate-dose cytarabine was delivered after standard "7+3" only if patients had 5% or more bone marrow blasts 15 days after chemotherapy initiation (d15-blasts). Of 823 included patients, 795 (96.6%) were evaluable...
January 2014: Haematologica
https://www.readbyqxmd.com/read/23841729/retinoic-acid-and-arsenic-trioxide-for-acute-promyelocytic-leukemia
#15
RANDOMIZED CONTROLLED TRIAL
Francesco Lo-Coco, Giuseppe Avvisati, Marco Vignetti, Christian Thiede, Sonia Maria Orlando, Simona Iacobelli, Felicetto Ferrara, Paola Fazi, Laura Cicconi, Eros Di Bona, Giorgina Specchia, Simona Sica, Mariadomenica Divona, Alessandro Levis, Walter Fiedler, Elisa Cerqui, Massimo Breccia, Giuseppe Fioritoni, Helmut R Salih, Mario Cazzola, Lorella Melillo, Angelo M Carella, Christian H Brandts, Enrica Morra, Marie von Lilienfeld-Toal, Bernd Hertenstein, Mohammed Wattad, Michael Lübbert, Matthias Hänel, Norbert Schmitz, Hartmut Link, Maria Grazia Kropp, Alessandro Rambaldi, Giorgio La Nasa, Mario Luppi, Fabio Ciceri, Olimpia Finizio, Adriano Venditti, Francesco Fabbiano, Konstanze Döhner, Michaela Sauer, Arnold Ganser, Sergio Amadori, Franco Mandelli, Hartmut Döhner, Gerhard Ehninger, Richard F Schlenk, Uwe Platzbecker
BACKGROUND: All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of treatment with arsenic trioxide with or without ATRA have shown high efficacy and reduced hematologic toxicity. METHODS: We conducted a phase 3, multicenter trial comparing ATRA plus chemotherapy with ATRA plus arsenic trioxide in patients with APL classified as low-to-intermediate risk (white-cell count, ≤10×10(9) per liter)...
July 11, 2013: New England Journal of Medicine
https://www.readbyqxmd.com/read/23692641/high-response-rate-and-acceptable-toxicity-of-a-combination-of-rituximab-vinorelbine-ifosfamide-mitoxantrone-and-prednisone-for-the-treatment-of-diffuse-large-b-cell-lymphoma-in-first-relapse-results-of-the-r-nimp-goelams-study
#16
MULTICENTER STUDY
Emmanuel Gyan, Diane Damotte, Stéphane Courby, Delphine Sénécal, Philippe Quittet, Aline Schmidt-Tanguy, Anne Banos, Steven Le Gouill, Thierry Lamy, Jean Fontan, Hervé Maisonneuve, Magda Alexis, Francois Dreyfus, Olivier Tournilhac, Kamel Laribi, Philippe Solal-Céligny, Nina Arakelyan, Guillaume Cartron, Remy Gressin
The optimal management of relapsed diffuse large B-cell lymphoma (DLBCL) is not standardized. The Groupe Ouest Est des Leucémies et aAutres Maladies du Sang developed a combination of vinorelbine, ifosfamide, mitoxantrone and prednisone (NIMP) for the treatment of relapsed DLBCL, and assessed its efficacy and safety in association with rituximab (R). This multicentric phase II study included 50 patients with DLBCL in first relapse, aged 18-75 years. Patients received rituximab 375 mg/m² day 1, ifosfamide 1000 mg/m² days 1-5, vinorelbine 25 mg/m² days 1 and 15, mitoxantrone 10 mg/m² day 1, and prednisone 1 mg/kg days 1-5, every 28 days for three cycles...
July 2013: British Journal of Haematology
https://www.readbyqxmd.com/read/23645686/symptomatic-osteonecrosis-in-childhood-leukemia-survivors-prevalence-risk-factors-and-impact-on-quality-of-life-in-adulthood
#17
MULTICENTER STUDY
Pauline Girard, Pascal Auquier, Vincent Barlogis, Audrey Contet, Maryline Poiree, François Demeocq, Julie Berbis, Iris Herrmann, Virginie Villes, Nicolas Sirvent, Justyna Kanold, Pascal Chastagner, Hervé Chambost, Dominique Plantaz, Gérard Michel
Corticosteroid can induce osteonecrosis in children with leukemia. Few studies have been designed to assess the influence of a wide range of cumulative steroid dose on this side effect. Prevalence, risk factors of symptomatic osteonecrosis and its impact on adults' Quality of Life were assessed in 943 patients enrolled in the French "Leucémies de l'Enfant et de l'Adolescent" (LEA) cohort of childhood leukemia survivors. During each medical visit, data on previous osteonecrosis diagnosis were retrospectively collected...
July 2013: Haematologica
https://www.readbyqxmd.com/read/23432206/flow-cytometry-thresholds-of-myeloperoxidase-detection-to-discriminate-between-acute-lymphoblastic-or-myeloblastic-leukaemia
#18
MULTICENTER STUDY
Julien Guy, Iléana Antony-Debré, Emmanuel Benayoun, Isabelle Arnoux, Chantal Fossat, Magali Le Garff-Tavernier, Anna Raimbault, Michèle Imbert, Marc Maynadié, Francis Lacombe, Marie C Béné, Orianne Wagner-Ballon
The World Health Organization 2008 Classification emphasizes myeloperoxidase (MPO) detection as sufficient for assigning a blast population to the myeloid lineage. Published MPO positivity thresholds are 10% for flow cytometry (FCM) but 3% for cytochemistry. Here we re-evaluated the FCM-MPO threshold by comparing retrospectively 128 acute lymphoblastic leukaemias and 75 acute myeloid leukaemias without maturation, all assessed by benzidine-based cytochemistry. A 13% threshold was found to be relevant using an isotype control as background-reference (sensitivity 95·1%, specificity 91·7%)...
May 2013: British Journal of Haematology
https://www.readbyqxmd.com/read/23321953/a-phase-ib-goelams-study-of-the-mtor-inhibitor-rad001-in-association-with-chemotherapy-for-aml-patients-in-first-relapse
#19
MULTICENTER STUDY
S Park, N Chapuis, F Saint Marcoux, C Recher, T Prebet, P Chevallier, J-Y Cahn, T Leguay, P Bories, F Witz, T Lamy, P Mayeux, C Lacombe, C Demur, J Tamburini, A Merlat, R Delepine, N Vey, F Dreyfus, M C Béné, N Ifrah, D Bouscary
The mTORC1 signaling pathway is constitutively activated in almost all acute myelogenous leukemia (AML) patients. We conducted a phase Ib trial combining RAD001 (everolimus), an allosteric inhibitor of mTORC1, and conventional chemotherapy, in AML patients under 65 years of age at first relapse (clinical trial NCT 01074086). Increasing doses of RAD001 from 10-70 mg were administrated orally on days 1 and 7 (d1 and d7) of a 3+7 daunorubicin+cytarabine conventional induction chemotherapy regimen. Twenty-eight patients were enrolled in this trial...
July 2013: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/23065509/chromosomal-aberrations-and-their-prognostic-value-in-a-series-of-174-untreated-patients-with-waldenstr%C3%A3-m-s-macroglobulinemia
#20
RANDOMIZED CONTROLLED TRIAL
Florence Nguyen-Khac, Jerome Lambert, Elise Chapiro, Aurore Grelier, Sarah Mould, Carole Barin, Agnes Daudignon, Nathalie Gachard, Stéphanie Struski, Catherine Henry, Dominique Penther, Hossein Mossafa, Joris Andrieux, Virginie Eclache, Chrystèle Bilhou-Nabera, Isabelle Luquet, Christine Terre, Laurence Baranger, Francine Mugneret, Jean Chiesa, Marie-Joelle Mozziconacci, Evelyne Callet-Bauchu, Lauren Veronese, Hélène Blons, Roger Owen, Julie Lejeune, Sylvie Chevret, Hélène Merle-Beral, Véronique Leblondon
Waldenström's macroglobulinemia is a disease of mature B cells, the genetic basis of which is poorly understood. Few recurrent chromosomal abnormalities have been reported, and their prognostic value is not known. We conducted a prospective cytogenetic study of Waldenström's macroglobulinemia and examined the prognostic value of chromosomal aberrations in an international randomized trial. The main aberrations were 6q deletions (30%), trisomy 18 (15%), 13q deletions (13%), 17p (TP53) deletions (8%), trisomy 4 (8%), and 11q (ATM) deletions (7%)...
April 2013: Haematologica
keyword
keyword
36175
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"